Stamulumab
Wyeth's first-generation anti-myostatin monoclonal antibody — discontinued in 2008 after Phase 1/2 in muscular dystrophies.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
The original anti-myostatin antibody program. Stamulumab established that direct myostatin neutralization was tolerable but did not produce meaningful functional benefits in adult muscular dystrophy patients in early trials.
- Class
- Anti-myostatin monoclonal antibody
- Sponsor
- Wyeth (acquired by Pfizer in 2009)
- Stage
- Phase 2 (discontinued 2008)
- Lead use case
- Adult muscular dystrophies
What it is
Stamulumab (MYO-029) is a recombinant human monoclonal antibody designed to bind and neutralize circulating myostatin. It was the first anti-myostatin biologic to advance into clinical trials in humans and is the historical anchor of the broader myostatin-inhibitor development effort.
Current research status
Wyeth advanced stamulumab into a Phase 1/2 trial in adult patients with various muscular dystrophies (Becker, facioscapulohumeral, and limb-girdle). The trial reported acceptable safety but did not meet efficacy endpoints for muscle strength or function. Wyeth discontinued the program in 2008. Pfizer acquired Wyeth in 2009 but did not resurrect stamulumab; the company's later anti-myostatin work centered on domagrozumab (PF-06252616).
Mechanistic rationale
Direct neutralization of mature myostatin in circulation, preventing it from engaging ActRIIB on muscle cells. The mechanistic rationale was clean — preclinical models had shown that myostatin loss-of-function (genetic or pharmacologic) produces dramatic muscle hypertrophy in mice, cattle, and dogs. The clinical translation, however, proved more complicated: adult patients with established muscular dystrophy may have insufficient regenerative capacity for myostatin blockade alone to restore meaningful function.
Available evidence
Phase 1/2 muscular dystrophy trial (Wagner et al., Ann Neurol 2008) — Adults with Becker, facioscapulohumeral, or limb-girdle muscular dystrophy received stamulumab over six months. The drug was generally well tolerated but did not produce significant improvements in muscle strength or function compared to placebo.[1]
This negative readout was a substantial shock to the field — the preclinical case for myostatin blockade had been so strong that the absence of clinical benefit prompted a re-examination of which patient populations and disease stages would be appropriate targets.
Why it's interesting
Stamulumab is the historical foundation of the entire anti-myostatin biologic class. Its negative trial reshaped the field: subsequent programs (domagrozumab, apitegromab, bimagrumab, trevogrumab) have systematically explored alternative selectivity profiles, alternative target ligands (latent myostatin, ActRIIB receptor blockade), and alternative patient populations (pediatric DMD, sarcopenia, GLP-1-induced muscle loss) in response to the lessons stamulumab provided. Understanding why stamulumab failed in adult muscular dystrophy is part of understanding why the field looks the way it does today.
Limitations & risks
The molecule has been discontinued for nearly two decades. It is not in active development, not commercially available, and not represented in the current research pipeline. Its primary value at this point is historical context for understanding the modern myostatin-inhibitor landscape.
Community discussion notes
Rarely discussed in contemporary fitness or biohacker communities — the conversation has moved on to active programs like bimagrumab and apitegromab. Mentioned occasionally in academic reviews of muscle pharmacology as the foundational case study in why direct myostatin blockade did not produce the dramatic functional benefits the preclinical work had suggested.
The takeaway
Stamulumab is a discontinued first-generation anti-myostatin antibody whose primary value is historical. The negative Phase 1/2 trial reshaped the field's selectivity, target, and patient-population thinking. Anyone seeking active anti-myostatin therapeutics should look to the successor programs — bimagrumab, apitegromab, trevogrumab — rather than to stamulumab itself.
References
- Wagner KR, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63(5):561-571. https://pubmed.ncbi.nlm.nih.gov/18335515/
- Bogdanovich S, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002;420(6914):418-421. https://pubmed.ncbi.nlm.nih.gov/12459784/